| T5995 |
Larotrectinib
|
1223403-58-4
|
100%
|
|
|
Larotrectinib (LOXO-101) is an orally administered inhibitor of the TRK kinase and is highly selective only for the TRK family of receptors(IC50s = 2-20 nM).
|
| T1704 |
Diosmetin
|
520-34-3
|
100%
|
|
|
Diosmetin (Luteolin 4-methyl ether) has been found to act as a weak TrkB receptor agonist.
|
| T9292 |
ALE-0540
|
234779-34-1
|
97.25%
|
|
|
ALE-0540 is a nonpeptidic heterocyclic molecule that inhibits the binding of NGF to p75 and TrkA, as well as signal transduction and biological responses mediate...
|
| T9496 |
LOXO-195
|
1350884-56-8
|
97.92%
|
|
|
(6RS)-LOXO-195 (BAY 2731954) is a potent and selective Trk tyrosine kinase inhibitor.
|
| T7568 |
LM22A-4
|
37988-18-4
|
98%
|
|
|
LM22A-4 is a brain-derived neurotrophic factor (BDNF) mimetic and agonist of the receptor tropomyosin-related kinase B (TrkB; IC50 : 47 nM in a fluorescence anis...
|
| T5635 |
CH7057288
|
2095616-82-1
|
98%
|
|
|
CH7057288 is an effective and selective TRK inhibitor with an IC50 value of 1.1 nM, 7.8 nM and 5.1 nM for TRKA, TRKB and TRKC, respectively.
|
| T19649 |
PF-06273340
|
1402438-74-7
|
98.00%
|
|
|
PF-06273340 is an effective, Selective, and Peripherally Restricted Pan-Trk inhibitor (IC50: Trk-A = 6 nM; Trk-B = 4 nM; Trk-C = 3 nM). PF-06273340 has low metab...
|
| T4496 |
LM22B-10
|
342777-54-2
|
98.19%
|
|
|
LM22B-10 is an activator of TrkB/TrkC neurotrophin receptor and can induce TrkB, TrkC, ERK and AKT activation in vitro and in vivo.
|
| T41224 |
CG 428
|
2412055-93-5
|
98.26%
|
|
|
CG 428 is a potent tropomyosin receptor Kinase (TRK) Degrader (uSMITETM) with a DC50 of 0.36 nM. CG 428 comprises an analog of the pan-TRK inhibitor GNF-8625 jo...
|
| T8327 |
ONO-7475
|
1646839-59-9
|
98.33%
|
|
|
ONO-7475 is an inhibitor with high specificity for anexelekto and MER tyrosine kinase
|
| T6121 |
Tepotinib
|
1100598-32-0
|
98.37%
|
|
|
Tepotinib (EMD-1214063) is an inhibitor of MET tyrosine kinase with potential antineoplastic activity.
|
| T2094 |
Danusertib
|
827318-97-8
|
98.44%
|
|
|
Danusertib (PHA-739358) is a small-molecule 3-aminopyrazole derivative with potential antineoplastic activity. Danusertib binds to and inhibits the Aurora kinase...
|
| T2349 |
BMS-754807
|
1001350-96-4
|
98.86%
|
|
|
Dual IGF-1R/InsR Inhibitor BMS-754807 is an oral small molecule inhibitor of insulin-like growth factor 1 receptor (IGF-1R) and insulin receptor (InsR) tyrosine ...
|
| T6052 |
GW 441756
|
504433-23-2
|
98.99%
|
|
|
GW 441756 is a specific Tropomyosin-related kinase A (TrkA) inhibitor with an IC50 value of 2 nM.
|
| T14921 |
CE-245677
|
717899-97-3
|
98.99%
|
|
|
CE-245677 is a potent reversible inhibitor of Tie2 and TrkA/B kinases. With a cellular IC50s of 4.7 and 1 nM.
|
| T6712 |
Tyrphostin AG 879
|
148741-30-4
|
99.05%
|
|
|
Tyrphostin AG 879 (AG 879) effectively inhibits HER2/ErbB2 (IC50: 1 μM), 100- and 500-fold higher selective to ErbB2 than EGFR and PDGFR.
|
| T73397 |
ENT-C225
|
2919962-53-9
|
99.16%
|
|
|
ENT-C225 is a potent TrkB neurotrophin receptor (TrkBR) activator with neuroprotective activity for the study of Alzheimer's disease and Parkinson's disease.
|
| T22324 |
Ensartinib hydrochloride
|
2137030-98-7
|
99.29%
|
|
|
Ensartinib hydrochloride (X-396 dihydrochloride) is a potent new-generation ALK inhibitor with high activity against CNS metastases and a broad range of known cr...
|
| T6097 |
GNF-5837
|
1033769-28-6
|
99.29%
|
|
|
GNF-5837 is a specific, and orally bioavailable pan-TRK inhibitor for TrkA/TrkB (IC50: 8/12 nM).
|
| T6057 |
URMC-099
|
1229582-33-5
|
99.32%
|
|
|
URMC-099 is an orally bioavailable, brain penetrant MLK inhibitor (IC50: 19/42/14/150 nM, for MLK1/MLK2/MLK3/DLK), and also inhibits LRRK2 activity (IC50: 11 nM)...
|
